Advanced search
Publication Cover
Leukemia & Lymphoma Volume 54, 2013 - Issue 4
Submit an article Journal homepage
1,345
Views
61
CrossRef citations to date
0
Altmetric
Research Article

Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies

Amir Hossein DaneshmaneshImmune and Gene Therapy Laboratory, Cancer Center Karolinska, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden;Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden
,
Anna PorwitDepartment of Pathology, Karolinska University Hospital Solna, Stockholm, Sweden;Department of Laboratory Medicine and Pathology, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada
,
Mohammad Hojjat-FarsangiDepartment of Oncology and Pathology, Cancer Center Karolinska, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden
,
Mahmood Jeddi-TehraniMonoclonal Antibody Research Center, Avicenna Research Institute (ACECR), Tehran, Iran
,
Katja Pokrovskaja TammDepartment of Oncology and Pathology, Cancer Center Karolinska, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden
,
Dan GrandérDepartment of Oncology and Pathology, Cancer Center Karolinska, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden
,
Sören LehmannHematology Center, Karolinska University Hospital Huddinge, Stockholm, Sweden
,
Stefan NorinHematology Center, Karolinska University Hospital Huddinge, Stockholm, Sweden;Division of Hematology, Department of Medicine at Huddinge, Karolinska Institutet, Stockholm, Sweden
,
Fazel ShokriMonoclonal Antibody Research Center, Avicenna Research Institute (ACECR), Tehran, Iran;Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
,
Hodjattallah RabbaniMonoclonal Antibody Research Center, Avicenna Research Institute (ACECR), Tehran, Iran
,
Håkan MellstedtImmune and Gene Therapy Laboratory, Cancer Center Karolinska, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden;Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden;Departments of Oncology (Radiumhemmet) and Hematology, Karolinska University Hospital Solna, Stockholm, SwedenCorrespondence[email protected]
&
Anders ÖsterborgImmune and Gene Therapy Laboratory, Cancer Center Karolinska, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden;Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden;Departments of Oncology (Radiumhemmet) and Hematology, Karolinska University Hospital Solna, Stockholm, Sweden
 show all
Pages 843-850 | Received 07 May 2012, Accepted 14 Sep 2012, Published online: 09 Oct 2012

Citations (61)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Efstathios T. Pavlidis & Theodoros E. Pavlidis. (2019) A Review of Primary Thyroid Lymphoma: Molecular Factors, Diagnosis and Management. Journal of Investigative Surgery 32:2, pages 137-142.
Read now
Mohammad Hojjat-Farsangi. (2016) Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances. Journal of Drug Targeting 24:3, pages 192-211.
Read now
Mahdi Shabani, Jila Naseri & Fazel Shokri. (2015) Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapy. Expert Opinion on Therapeutic Targets 19:7, pages 941-955.
Read now

Articles from other publishers (58)

Amineh Ghaderi, Mohammad-Ali Okhovat, Jemina Lehto, Luigi De Petris, Ehsan Manouchehri Doulabi, Parviz Kokhaei, Wen Zhong, Georgios Z. Rassidakis, Elias Drakos, Ali Moshfegh, Johan Schultz, Thomas Olin, Anders Österborg, Håkan Mellstedt & Mohammad Hojjat-Farsangi. (2023) A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells. Pharmaceutics 15:4, pages 1148.
Crossref
Elsa Maitre, Jerome Paillassa & Xavier Troussard. (2022) Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders. Frontiers in Oncology 12.
Crossref
Thomas J. Kipps. (2022) ROR1: an orphan becomes apparent. Blood 140:14, pages 1583-1591.
Crossref
Salvatore R. Guarino, Antonella Di Bello, Martina Palamini, Maria Chiara Capillo & Federico Forneris. (2022) Crystal structure of the kringle domain of human receptor tyrosine kinase-like orphan receptor 1 (hROR1). Acta Crystallographica Section F Structural Biology Communications 78:5, pages 185-192.
Crossref
Andrea Iannello, Silvia Deaglio & Tiziana Vaisitti. (2022) Novel Approaches for the Treatment of Patients with Richter’s Syndrome. Current Treatment Options in Oncology 23:4, pages 526-542.
Crossref
Michael L. Wang, Jacqueline C. Barrientos, Richard R. Furman, Matthew Mei, Paul M. Barr, Michael Y. Choi, Sven de Vos, Avyakta Kallam, Krish Patel, Thomas J. Kipps, Simon Rule, Kate Flanders, Katti A. Jessen, Hong Ren, Peter C. Riebling, Patricia Graham, Lydia King, Archie W. Thurston, Michael Sun, Elizabeth M. Schmidt, Brian J. Lannutti, David M. Johnson, Langdon L. Miller & Stephen E. Spurgeon. (2022) Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers. NEJM Evidence 1:1.
Crossref
Vanshika Rustagi, Garima Nagar, Pooja Mittal, Archana Singh & Indrakant Kumar Singh. 2022. Protein Kinase Inhibitors. Protein Kinase Inhibitors 597 621 .
Yazeed Sawalha. (2021) Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies. Journal of Personalized Medicine 11:12, pages 1345.
Crossref
Nicholas W. Chavkin, Soichi Sano, Ying Wang, Kosei Oshima, Hayato Ogawa, Keita Horitani, Miho Sano, Susan MacLauchlan, Anders Nelson, Karishma Setia, Tanvi Vippa, Yosuke Watanabe, Jeffrey J. Saucerman, Karen K. Hirschi, Noyan Gokce & Kenneth Walsh. (2021) The Cell Surface Receptors Ror1/2 Control Cardiac Myofibroblast Differentiation. Journal of the American Heart Association 10:13.
Crossref
Tiziana Vaisitti, Francesca Arruga, Nicoletta VitaleThanh-Trang Lee, Mira KoAmy ChadburnEsteban Braggio, Arianna Di Napoli, Andrea Iannello, John N. Allan, Langdon L. MillerBrian J. LannuttiRichard R. FurmanKatti A. JessenSilvia Deaglio. (2021) ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models. Blood 137:24, pages 3365-3377.
Crossref
Claudio Ortolani. 2021. Flow Cytometry of Hematological Malignancies. Flow Cytometry of Hematological Malignancies 301 427 .
Hisanori Isomura, Ayumu Taguchi, Taisuke Kajino, Naoya Asai, Masahiro Nakatochi, Seiichi Kato, Keiko Suzuki, Kiyoshi Yanagisawa, Motoshi Suzuki, Teruaki Fujishita, Tomoya Yamaguchi, Masahide Takahashi & Takashi Takahashi. (2021) Conditional Ror1 knockout reveals crucial involvement in lung adenocarcinoma development and identifies novel HIF‐1α regulator . Cancer Science 112:4, pages 1614-1623.
Crossref
Behnoush Khaledian, Ayumu Taguchi, Kazuo Shin‐ya, Lisa Kondo‐Ida, Noritaka Kagaya, Motoshi Suzuki, Taisuke Kajino, Tomoya Yamaguchi, Yukako Shimada & Takashi Takahashi. (2021) Inhibition of heat shock protein 90 destabilizes receptor tyrosine kinase ROR1 in lung adenocarcinoma. Cancer Science 112:3, pages 1225-1234.
Crossref
Kerstin Menck, Saskia Heinrichs, Cornelia Baden & Annalen Bleckmann. (2021) The WNT/ROR Pathway in Cancer: From Signaling to Therapeutic Intervention. Cells 10:1, pages 142.
Crossref
A.S. Gorbenko, M.A. Stolyar, V.I. Bakhtina, E.V. Martynova, V.I. Moskov, M.A. Mikhalev, T.I. Olkhovik, A.S. Hazieva, M.G. Smelyanskaya & I.A. Olkhovskiy. (2021) Development of a method for determining of the mRNA ROR1 in blood leukocytes. Laboratornaya sluzhba 10:1, pages 32.
Crossref
Amir-Hassan Zarnani, Davood Jafari, Mahmood Bozorgmehr, Mahdi Shabani, Leila Barzegar-Yarmohammadi, Fatemeh Ghaemimanesh & Mahmood Jeddi-Tehrani. 2021. Cancer Immunology. Cancer Immunology 273 312 .
Mohammad Hojjat-Farsangi, Ali Moshfegh, Johan Schultz, Martin Norin, Thomas Olin, Anders Österborg & Håkan Mellstedt. 2021. Pharmacology of the WNT Signaling System. Pharmacology of the WNT Signaling System 75 99 .
Giovanna Schiavone, Samantha Epistolio, Vittoria Martin, Francesca Molinari, Jessica Barizzi, Luca Mazzucchelli, Milo Frattini & Luciano Wannesson. (2020) Functional and clinical significance of ROR1 in lung adenocarcinoma. BMC Cancer 20:1.
Crossref
Pavlína Janovská, Emmanuel Normant, Hari Miskin & Vítězslav Bryja. (2020) Targeting Casein Kinase 1 (CK1) in Hematological Cancers. International Journal of Molecular Sciences 21:23, pages 9026.
Crossref
Maria Stefania De Propris, Stefania Intoppa, Maria Laura Milani, Paola Mariglia, Maria Grazia Nardacci, Nadia Peragine, Robin Foà & Anna Guarini. (2020) ROR1 is an accurate and reliable marker of minimal residual disease in chronic lymphocytic leukaemia. British Journal of Haematology 190:6.
Crossref
Joshua B. Sheetz, Sebastian Mathea, Hanna Karvonen, Ketan Malhotra, Deep Chatterjee, Wilhelmiina Niininen, Robert Perttilä, Franziska Preuss, Krishna Suresh, Steven E. Stayrook, Yuko Tsutsui, Ravi Radhakrishnan, Daniela Ungureanu, Stefan Knapp & Mark A. Lemmon. (2020) Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases. Molecular Cell 79:3, pages 390-405.e7.
Crossref
Amineh Ghaderi, Amir Hossein Daneshmanesh, Ali Moshfegh, Parviz Kokhaei, Jan Vågberg, Johan Schultz, Thomas Olin, Sara Harrysson, Karin E Smedby, Elias Drakos, Georgios Z. Rassidakis, Anders Österborg, Håkan Mellstedt & Mohammad Hojjat-Farsangi. (2020) ROR1 is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells. Biomedicines 8:6, pages 170.
Crossref
Yu. V. Mirolyubova, N. S. Timofeeva, V. A. Bart, V. M. Solovyov, E. V. Tolstopyatova, E. S. Fetisov, V. V. Strugov, A. Yu. Zaritsky & T. V. Vavilova. (2020) Orphan receptor ROR1 for detection of minimal residual disease in chronic lymphocytic leukemia. Medical alphabet:5, pages 19-24.
Crossref
Jung-Hyun Shin, Hye-Jung Yoon, Soung-Min Kim, Jong-Ho Lee & Hoon Myoung. (2020) Analyzing the factors that influence occult metastasis in oral tongue cancer. Journal of the Korean Association of Oral and Maxillofacial Surgeons 46:2, pages 99-107.
Crossref
Tiffany-Heather Ulep, Ryan Zenhausern, Alana Gonzales, David S. Knoff, Paula A. Lengerke Diaz, Januario E. Castro & Jeong-Yeol Yoon. (2020) Smartphone based on-chip fluorescence imaging and capillary flow velocity measurement for detecting ROR1+ cancer cells from buffy coat blood samples on dual-layer paper microfluidic chip. Biosensors and Bioelectronics 153, pages 112042.
Crossref
Sanjay Kulkarni, Abhijeet Pandey & Srinivas Mutalik. (2020) Heterogeneous surface-modified nanoplatforms for the targeted therapy of haematological malignancies. Drug Discovery Today 25:1, pages 160-167.
Crossref
Zhengna Yin, Yuan Mao, Ningzhi Zhang, Yiping Su, Jin Zhu, Hua Tong & Huilin Zhang. (2019) A fully chimeric IgG antibody for ROR1 suppresses ovarian cancer growth in vitro and in vivo. Biomedicine & Pharmacotherapy 119, pages 109420.
Crossref
Yuan Mao, Li Xu, Jun Wang, Louqian Zhang, Nan Hou, Juqing Xu, Lin Wang, Shu Yang, Yan Chen, Lin Xiong, Jin Zhu, Weifei Fan & Jiaren Xu. (2019) ROR1 associates unfavorable prognosis and promotes lymphoma growth in DLBCL by affecting PI3K/Akt/mTOR signaling pathway. BioFactors 45:3, pages 416-426.
Crossref
Amir Hossein Daneshmanesh, Mohammad Hojjat-Farsangi, Amineh Ghaderi, Ali Moshfegh, Lotta Hansson, Johan Schultz, Jan Vågberg, Styrbjörn Byström, Elisabeth Olsson, Thomas Olin, Anders Österborg & Håkan Mellstedt. (2018) A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib. PLOS ONE 13:6, pages e0198038.
Crossref
Pavlina JanovskaJan VernerJiri KohoutekLenka BryjovaMichaela GregorovaMarta DzimkovaHana SkabrahovaTomasz RadaszkiewiczPetra OvesnaOlga Vondalova BlanarovaTereza NemcovaZuzana HoferovaKaterina VasickovaLucie SmyckovaAlexander Egle, Sarka Pavlova, Lucie Poppova, Karla Plevova, Sarka Pospisilova & Vitezslav Bryja. (2018) Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia. Blood 131:11, pages 1206-1218.
Crossref
Carol S. Leung. (2018) Analysis of ROR1 Protein Expression in Mice with Reconstituted Human Immune System Components. Journal of Immunology Research 2018, pages 1-10.
Crossref
Marzia Vezzalini, Andrea Mafficini, Luisa Tomasello, Erika Lorenzetto, Elisabetta Moratti, Zeno Fiorini, Tessa L. Holyoake, Francesca Pellicano, Mauro Krampera, Cristina Tecchio, Mohamed Yassin, Nader Al-Dewik, Mohamed A. Ismail, Ali Al Sayab, Maria Monne & Claudio Sorio. (2017) A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type γ in chronic myeloid leukemia patients. Journal of Hematology & Oncology 10:1.
Crossref
Pavlína Janovská & Vítězslav Bryja. (2017) Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas. British Journal of Pharmacology 174:24, pages 4701-4715.
Crossref
David G. Covell. (2017) A data mining approach for identifying pathway-gene biomarkers for predicting clinical outcome: A case study of erlotinib and sorafenib. PLOS ONE 12:8, pages e0181991.
Crossref
Ying Xu, Yan-Hui Ma, Ying-Xin Pang, Zhe Zhao, Jing-Jing Lu, Hong-Luan Mao & Pei-Shu Liu. (2017) Ectopic repression of receptor tyrosine kinase–like orphan receptor 2 inhibits malignant transformation of ovarian cancer cells by reversing epithelial–mesenchymal transition. Tumor Biology 39:5, pages 101042831770162.
Crossref
Hanna Karvonen, Wilhelmiina Niininen, Astrid Murumägi & Daniela Ungureanu. (2017) Targeting ROR1 identifies new treatment strategies in hematological cancers. Biochemical Society Transactions 45:2, pages 457-464.
Crossref
Leili Aghebati-Maleki, Vahid Younesi, Behzad Baradaran, Jalal Abdolalizadeh, Morteza Motallebnezhad, Hamid Nickho, Dariush Shanehbandi, Jafar Majidi & Mehdi Yousefi. (2017) Antiproliferative and Apoptotic Effects of Novel Anti-ROR1 Single-Chain Antibodies in Hematological Malignancies. SLAS Discovery 22:4, pages 408-417.
Crossref
Leili Aghebati-Maleki, Mahdi Shabani, Behzad Baradaran, Morteza Motallebnezhad, Jafar Majidi & Mehdi Yousefi. (2017) Receptor tyrosine kinase-like orphan receptor 1 (ROR-1): An emerging target for diagnosis and therapy of chronic lymphocytic leukemia. Biomedicine & Pharmacotherapy 88, pages 814-822.
Crossref
Leili Aghebati-Maleki, Vahid Younesi, Farhad Jadidi-Niaragh, Behzad Baradaran, Jafar Majidi & Mehdi Yousefi. (2017) Isolation and characterization of anti ROR1 single chain fragment variable antibodies using phage display technique. Human Antibodies 25:1-2, pages 57-63.
Crossref
Chunlai Li, Shouyu Wang, Zhen Xing, Aifu Lin, Ke Liang, Jian Song, Qingsong Hu, Jun Yao, Zhongyuan Chen, Peter K. Park, David H. Hawke, Jianwei Zhou, Yan Zhou, Shuxing Zhang, Han Liang, Mien-Chie Hung, Gary E. Gallick, Leng Han, Chunru Lin & Liuqing Yang. (2017) A ROR1–HER3–lncRNA signalling axis modulates the Hippo–YAP pathway to regulate bone metastasis. Nature Cell Biology 19:2, pages 106-119.
Crossref
Bing CuiEmanuela M. GhiaLiguang ChenLaura Z. RassentiChristopher DeBoever, George F. WidhopfIIIIJian YuDonna S. Neuberg, William G. WierdaKanti R. Rai, Neil E. Kay, Jennifer R. BrownJeffrey A. JonesJohn G. Gribben, Kelly A. Frazer & Thomas J. Kipps. (2016) High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood 128:25, pages 2931-2940.
Crossref
Xiao-Ying Zhang & Pei-Ying Zhang. (2016) Receptor tyrosine kinases in carcinogenesis. Oncology Letters 12:5, pages 3679-3682.
Crossref
Gholamreza Khamisipour, Farhad Jadidi-Niaragh, Abdolreza Sotoodeh Jahromi, Keivan zandi & Mohammad Hojjat-Farsangi. (2016) Mechanisms of tumor cell resistance to the current targeted-therapy agents. Tumor Biology 37:8, pages 10021-10039.
Crossref
Hyeyoon Chang, Woon Yong Jung, Youngran Kang, Hyunjoo Lee, Aeree Kim & Baek-hui Kim. (2015) Expression of ROR1, pAkt, and pCREB in gastric adenocarcinoma. Annals of Diagnostic Pathology 19:5, pages 330-334.
Crossref
Chenlin Lu, Xudong Wang, Huijun Zhu, Jian Feng, Songshi Ni & Jianfei Huang. (2015) Over-expression of ROR2 and Wnt5a cooperatively correlates with unfavorable prognosis in patients with non-small cell lung cancer. Oncotarget 6:28, pages 24912-24921.
Crossref
L. He, Z. Yang, J. Zhou & W. Wang. (2014) The clinical pathological significance of FRAT1 and ROR2 expression in cartilage tumors. Clinical and Translational Oncology 17:6, pages 438-445.
Crossref
Yanchun Liu, Hui Yang, Tianxing Chen, Yongbin Luo, Zheyuan Xu, Ying Li & Jiahui Yang. (2015) Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung Adenocarcinoma. PLOS ONE 10:5, pages e0127092.
Crossref
R Mani, Y Mao, F W Frissora, C-L Chiang, J Wang, Y Zhao, Y Wu, B Yu, R Yan, X Mo, L Yu, J Flynn, J Jones, L Andritsos, S Baskar, C Rader, M A Phelps, C-S Chen, R J Lee, J C Byrd, L J Lee & N Muthusamy. (2014) Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia. Leukemia 29:2, pages 346-355.
Crossref
Nadine KutschReinhard MarksRichard RateiThomas K. HeldMartin Schmidt-Hieber. (2015) Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms. Biomarker Insights 10s3, pages BMI.S22434.
Crossref
Amir-Hassan Zarnani, Mahmood Bozorgmehr, Mahdi Shabani, Leila Barzegar-Yarmohammadi, Fatemeh Ghaemimanesh & Mahmood Jeddi-Tehrani. 2015. Cancer Immunology. Cancer Immunology 293 328 .
Mohammad Hojjat-Farsangi, Ali Moshfegh, Amir Hossein Daneshmanesh, Abdul Salam Khan, Eva Mikaelsson, Anders Österborg & Håkan Mellstedt. (2014) The receptor tyrosine kinase ROR1 – An oncofetal antigen for targeted cancer therapy. Seminars in Cancer Biology 29, pages 21-31.
Crossref
Mohammad Hojjat-Farsangi. (2014) Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies. International Journal of Molecular Sciences 15:8, pages 13768-13801.
Crossref
Huilin Zhang, Jinrong Qiu, Chunping Ye, Dazhen Yang, Lingjuan Gao, Yiping Su, Xiaojun Tang, Ning Xu, Dawei Zhang, Lin Xiong, Yuan Mao, Fengshan Li & Jin Zhu. (2014) ROR1 expression correlated with poor clinical outcome in human ovarian cancer. Scientific Reports 4:1.
Crossref
Nicholas Borcherding, David Kusner, Guang-Hui Liu & Weizhou Zhang. (2014) ROR1, an embryonic protein with an emerging role in cancer biology. Protein & Cell 5:7, pages 496-502.
Crossref
Iveta M. Petrova, Martijn J. Malessy, Joost Verhaagen, Lee G. Fradkin & Jasprina N. Noordermeer. (2013) Wnt Signaling through the Ror Receptor in the Nervous System. Molecular Neurobiology 49:1, pages 303-315.
Crossref
Mohammad Hojjat-Farsangi, Abdul Salam Khan, Amir Hossein Daneshmanesh, Ali Moshfegh, Åsa Sandin, Ladan Mansouri, Marzia Palma, Jeanette Lundin, Anders Österborg & Håkan Mellstedt. (2013) The Tyrosine Kinase Receptor ROR1 Is Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) Cells. PLoS ONE 8:10, pages e78339.
Crossref
Mohammad Hojjat-Farsangi, Fatemeh Ghaemimanesh, Amir Hossein Daneshmanesh, Ali-Ahmad Bayat, Jafar Mahmoudian, Mahmood Jeddi-Tehrani, Hodjatallah Rabbani & Hakan Mellstedt. (2013) Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells. PLoS ONE 8:4, pages e61167.
Crossref
Sivasubramanian Baskar & Natarajan Muthusamy. (2012) Antibody-based Therapeutics for the Treatment of Human B cell Malignancies. Current Allergy and Asthma Reports 13:1, pages 33-43.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.